Nafazatrom - CISMeF

Preferred Label : Nafazatrom;

NCIt synonyms : 3H-pyrazol-3-one,2,4-dihydro-5-methyl-2-(2-(2-naphthalenyloxy)ethyl); 1-(2-(beta-naphthyloxy)ethyl)-3-methyl-2-pyrazolin-5-one;

NCIt definition : A pyrazolinone derivative with potential antimetastatic activities. Nafazatrom, originally developed as an antithrombotic agent, inhibits the key prostaglandin catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase, which prolongs the biological half-life of prostacyclin (prostaglandin I2; PGI2) and prevents intravascular coagulation. This agent also serves as a reducing cofactor with the hydroperoxidase moiety of cyclooxygenase and accelerates the conversion of arachidonic acid into precursors of PGI2. An elevated level of PGI2 prevents aggregation of platelets; subsequently it decreases the formation of tumor cell-platelet aggregates as well as their sequestration in blood vessels, which is an important initiating step in the development of metastasis.;

UNII : K94216221B;

InChIKey : ULPLLIRKFGAHTA-UHFFFAOYSA-N;

CAS number : 59040-30-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 59040-30-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : Bay-g 6575; Bay g 6575;

Chemical formula : C16H16N2O2;

Details

Origin ID

C1010;

UMLS CUI

C0053025;

Currated CISMeF NLP mapping
- nafazatrom [Substance BNPC]
- nafazatrom [MeSH concept]
- nafazatrom [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- nafazatrom [Substance BNPC]
- nafazatrom [MeSH concept]
- nafazatrom [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients